KR101508621B1 - 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 - Google Patents

활성화된 폴리옥사졸린 및 이를 포함하는 조성물 Download PDF

Info

Publication number
KR101508621B1
KR101508621B1 KR20137028233A KR20137028233A KR101508621B1 KR 101508621 B1 KR101508621 B1 KR 101508621B1 KR 20137028233 A KR20137028233 A KR 20137028233A KR 20137028233 A KR20137028233 A KR 20137028233A KR 101508621 B1 KR101508621 B1 KR 101508621B1
Authority
KR
South Korea
Prior art keywords
group
poz
delete delete
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20137028233A
Other languages
English (en)
Korean (ko)
Other versions
KR20130125404A (ko
Inventor
제이. 밀턴 해리스
마이클 데이비드 밴틀리
윤건상
치하오 팡
프란세스코 마리아 베로네스
Original Assignee
세리나 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세리나 쎄라퓨틱스, 인코포레이티드 filed Critical 세리나 쎄라퓨틱스, 인코포레이티드
Publication of KR20130125404A publication Critical patent/KR20130125404A/ko
Application granted granted Critical
Publication of KR101508621B1 publication Critical patent/KR101508621B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3412—Heterocyclic compounds having nitrogen in the ring having one nitrogen atom in the ring
    • C08K5/3415—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
KR20137028233A 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 Active KR101508621B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89221207P 2007-02-28 2007-02-28
US60/892,212 2007-02-28
PCT/US2008/002626 WO2008106186A2 (en) 2007-02-28 2008-02-28 Activated polyoxazolines and compositions comprising the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20097020124A Division KR101508617B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Publications (2)

Publication Number Publication Date
KR20130125404A KR20130125404A (ko) 2013-11-18
KR101508621B1 true KR101508621B1 (ko) 2015-04-07

Family

ID=39721806

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20137028233A Active KR101508621B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
KR20097020124A Active KR101508617B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20097020124A Active KR101508617B1 (ko) 2007-02-28 2008-02-28 활성화된 폴리옥사졸린 및 이를 포함하는 조성물

Country Status (6)

Country Link
US (1) US7943141B2 (https=)
EP (1) EP2134181A4 (https=)
JP (1) JP5615558B2 (https=)
KR (2) KR101508621B1 (https=)
CN (2) CN101686687A (https=)
WO (1) WO2008106186A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088884B2 (en) * 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
WO2013020005A2 (en) * 2011-08-03 2013-02-07 Anp Technologies, Inc. Oxazoline polymer compositions and use thereof
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US8383093B1 (en) * 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US9416228B2 (en) * 2012-03-16 2016-08-16 Bender Analytical Holding B.V. Cross-linked polymers and medical products derived from nucleophilically activated polyoxazoline
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
CN103897181B (zh) * 2012-12-27 2017-02-08 张昊 聚合物、其制备方法和应用
US9624191B2 (en) 2014-03-24 2017-04-18 International Business Machines Corporation Cyclic carbonate monomers and ring opened polycarbonates therefrom
US9215876B2 (en) 2014-03-24 2015-12-22 International Business Machines Corporation 1,3,6-dioxazocan-2-ones and antimicrobial cationic polycarbonates therefrom
GB201405391D0 (en) * 2014-03-26 2014-05-07 Applied Biomimetic As Novel polymers and process for making membranes
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN107075115B (zh) * 2014-07-18 2020-05-29 根特大学 一种用于制备均匀的高摩尔质量环亚氨醚聚合物的方法
US10071168B2 (en) * 2014-07-31 2018-09-11 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
BR112017006943B1 (pt) * 2014-10-06 2020-12-01 Gatt Technologies B.V produto hemostático poroso adesivo de tecido
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
AU2016335860B2 (en) 2015-10-08 2023-08-10 Nektar Therapeutics Combination of an IL-2Rbeta-selective agonist and a long-acting IL-15 agonist
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
EP3502217B1 (en) * 2017-11-29 2020-05-27 Infineum International Limited Lubricating oil compositions
US10822569B2 (en) 2018-02-15 2020-11-03 Afton Chemical Corporation Grafted polymer with soot handling properties
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US10851324B2 (en) 2018-02-27 2020-12-01 Afton Chemical Corporation Grafted polymer with soot handling properties
CN110865055B (zh) * 2018-08-27 2022-10-25 香港科技大学 无金属偶联方法、偶联物及其应用
US10899989B2 (en) 2018-10-15 2021-01-26 Afton Chemical Corporation Amino acid grafted polymer with soot handling properties
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
US11046908B2 (en) 2019-01-11 2021-06-29 Afton Chemical Corporation Oxazoline modified dispersants
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
US12485181B2 (en) 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
EP4004085B1 (en) * 2019-07-30 2025-07-30 Cilag GmbH International Polyoxazoline copolymer comprising calcium binding groups
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
CA3153644A1 (en) 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
CN117098558A (zh) 2021-02-09 2023-11-21 塞瑞纳治疗公司 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN118900701A (zh) 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
CN114685784B (zh) * 2022-04-26 2023-09-15 北京清科胜因生物科技有限公司 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用
CN114940756B (zh) * 2022-06-02 2023-11-07 北京清科胜因生物科技有限公司 一种聚（2-噁唑啉）脂质与脂质纳米颗粒及应用
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
CN118459756A (zh) * 2024-05-07 2024-08-09 南京师范大学 一种温敏性材料和糖缀合物及其合成方法和在糖固相合成中的应用
EP4656669A1 (en) 2024-05-28 2025-12-03 Arkema France Fluorinated copolymers based on an oligo(2-oxazoline) macromonomer
WO2026055280A1 (en) 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2643403B2 (ja) * 1989-01-10 1997-08-20 花王株式会社 ポリ（ｎ―アシルアルキレンイミン）系共重合体及びその用途
US5635571A (en) * 1995-06-30 1997-06-03 Cornell Research Foundation, Inc. Polymerizable macromonomers and polymers prepared therefrom
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP2004535401A (ja) * 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
EP1480657A4 (en) * 2002-02-01 2006-07-05 Intradigm Corp POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I
JP4805911B2 (ja) * 2004-03-15 2011-11-02 ネクター セラピューティクス Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
WO2007026932A1 (ja) * 2005-09-01 2007-03-08 Japan Science And Technology Agency オキサゾリンのランダム共重合体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., 2006, Vol. 17, pp. 781-786. *
Bioconjugate Chem., 2006, Vol. 17, pp. 781-786.*
Journal of pharmaceutical Sciences, Vol. 85, No. 2, 1996년 2월, pp. 133-137. *
Journal of pharmaceutical Sciences, Vol. 85, No. 2, 1996년 2월, pp. 133-137.*
Macromol. Chem. Phys. Vol. 197, 1996, pp. 2811-2826. *
Macromol. Chem. Phys. Vol. 197, 1996, pp. 2811-2826.*

Also Published As

Publication number Publication date
JP2010529212A (ja) 2010-08-26
US7943141B2 (en) 2011-05-17
WO2008106186A2 (en) 2008-09-04
US20100069579A1 (en) 2010-03-18
CN101686687A (zh) 2010-03-31
WO2008106186A3 (en) 2008-10-23
CN106046370A (zh) 2016-10-26
EP2134181A4 (en) 2011-09-28
KR20130125404A (ko) 2013-11-18
JP5615558B2 (ja) 2014-10-29
KR20090114481A (ko) 2009-11-03
EP2134181A2 (en) 2009-12-23
KR101508617B1 (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
KR101508621B1 (ko) 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
US9169354B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8088884B2 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
JP4877225B2 (ja) ポリオキシアルキレン誘導体
US11925689B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
AU2012301793A1 (en) Branched discrette PEG constructs
US10864276B2 (en) Activated polyoxazolines and conjugates and compositions comprising the same
WO2022266498A1 (en) Histidine-selective polymer reagents
WO2026031745A1 (zh) 一种氮支化两臂聚乙二醇衍生物的制备方法
Lin Synthesis of Poly (ethylene glycol) Derivatives for Bioconjugation and Surface Patterning

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131025

Application number text: 1020097020124

Filing date: 20090925

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140213

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140825

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150330

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150330

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180402

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180402

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190325

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190325

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20200330

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20200330

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20210617

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20210617

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20220908

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20220908

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230329

Start annual number: 9

End annual number: 9